About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A Study of ABT-751 in Patients With Renal Cell Cancer

NCT00073112·23 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Abbott

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Renal Cell Carcinoma.
Recurrent tumor.
At least 6 weeks post-nephrectomy.
Able to tolerate normal activities of daily living.
Adequate bone marrow, kidney, and liver function.

You may not be if

Pregnant or breast feeding.
Anti-tumor therapy within 4 weeks of the start of ABT-751 administration.
CNS metastasis.

The record

StatusCompleted

PhasePhase 2

Taking part60

StartedAug 2003

UpdatedNov 29, 2007

Conditions

Renal Cell Cancer

Where23

Arizona Cancer Research Center
Tucson, Arizona, United States
UCLA School of Medicine
Los Angeles, California, United States
Clinical Trials + Research Associates
Montebello, California, United States

Clareo Health | A Study of ABT-751 in Patients With Renal Cell Cancer